Prostate Sustained Release Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Benign Prostatic Hyperplasia (BPH) often require invasive procedures, have significant side effects, and provide limited sustained efficacy, necessitating a more effective and less invasive approach for managing lower urinary tract symptoms.
Innovation Solution
A minimally invasive treatment using a sustained release formulation delivered via a needle or catheter, which includes a cytostatic or cytotoxic drug, administered transrectally or transperineally to target the prostate tissue, providing localized relief with reduced risk of adverse effects and improved patient acceptance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral medications are prescribed for BPH treatment, then patient compliance is maintained through daily dosing, but side effects such as ejaculation changes, erectile dysfunction, and decreased libido occur
Solution Approach 1:
The patent extracts the active drug from systemic circulation and delivers it directly to the prostate tissue through a catheter, eliminating the need for oral administration and avoiding systemic side effects while maintaining therapeutic efficacy
Solution Approach 2:
The patent uses a sustained-release formulation as an intermediary carrier that delivers the drug directly to the prostate, acting as a mediator between the drug and target tissue to achieve localized treatment without systemic exposure
2Reliability
If invasive procedures are used for BPH treatment, then sustained efficacy is achieved, but patient trauma and recovery time increase
Solution Approach 1:
The patent replaces mechanical surgical intervention with a minimally invasive catheter-based drug delivery system that achieves sustained efficacy through controlled local drug release rather than physical tissue removal or destruction
Solution Approach 2:
The patent changes the delivery parameters from systemic oral administration to localized continuous release, achieving sustained therapeutic concentrations at the target site while minimizing overall drug exposure and patient trauma
3Ease of operation
If transurethral approach is used for drug delivery, then access to prostate tissue is achieved, but caustic effects on urethra and dysuria occur
Solution Approach 1:
The patent segments the drug delivery pathway from the urethra by introducing the catheter through the rectum, separating the administration route from the target tissue to avoid direct contact and caustic effects on the urethra
Solution Approach 2:
The patent uses the rectal wall as an intermediary barrier that allows catheter access to the prostate without direct urethral involvement, mediating between the external environment and the target tissue while protecting the urethra from damage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment achieves sustained efficacy over several months with reduced side effects and less invasive procedures, effectively managing BPH symptoms by targeting the prostate tissue with minimal diffusion to surrounding areas, thus minimizing urinary and sexual dysfunction risks.
Implementation Method 1
delivery of a drug or multiple drugs to the tissue in a sustained release manner via the sustained release formulation
Data Source
AI summary
A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.